These findings demonstrated that NR6A1, OSBP2 and UNC119B might play a critical role in HCC immunotherapy, suggesting that Kla might be regarded as a novel immunotherapeutic target for HCC. The gene discussed is OSBP2; the disease is hepatocellular carcinoma.